Sun Pharma Q4 Profits

• 

  Sun Pharma Slides Over 4% Post March Quarter Results

  Sun Pharma posted a net profit to Rs 894 crore in the fourth quarter ended March 2021, which is a rise of 124 per cent compared to the same quarter last year

• 

  Sun Pharma Stock Slip 4% As Quarterly Earnings Decline

  The drug major saw a 14 percent dip in consolidated net profit in Q4 due to pricing pressure in the US market.

• 

  Sun Pharma Shares Slump On Q4 Profit Miss, Revenue Guidance

  Sun Pharmaceutical Industries shares slumped over 5 per cent on Tuesday, following the drugmaker's fourth quarter earnings announcement. Sun Pharmaceutical, India's largest drugmaker, was the top Nifty50 loser today.

• 

  Sun Pharma Fourth Quarter Profit Almost Doubles But Misses Estimates

  Sun Pharmaceutical Industries Ltd reported a near-doubling in fourth-quarter profit, although that missed analysts' estimates as weakness in emerging markets outweighed higher sales in India and the United States.

• 

  Sun Pharma Gets US Summons Over Drug Pricing, Shares Flat

  The US Department of Justice (DoJ) on Saturday sought information from Sun Pharma about pricing and marketing of generic drugs that it sells in that country.

• 

  Sun Pharma Shares Jump On Taro's Q4

  Sun Pharmaceuticals shares jumped over 5 per cent on Friday after the drugmaker's US-based subsidiary Taro Pharma reported strong earnings.

• 

  Sun Pharma Misses Profit Estimates in Q4 on Ranbaxy Costs

  Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.

• 

  Sun Pharma Q4 Net Profit Rises 57 Per Cent to Rs 1,587 Crore

  Sun Pharmaceutical Industries Ltd, India's third-largest drugmaker by revenue, on Thursday reported a 57 per cent jump in fourth-quarter net profit, slightly above expectations, helped by higher sales in the United States, its largest market.

• Sun Pharma Q4 Profit Seen at Rs 1,335 Crore: StarMine

  StarMine's SmartEstimates, which places a greater emphasis on forecasts by top-rated analysts, expects Sun Pharma to report profit of Rs 1,335 crore ($226.75 million) for the quarter, compared with a consensus mean estimate of Rs 1,574 crore.

• 

  Sun Pharma Falls; Unit Taro Results Fail to Beat Estimates

  Taro's revenue in January-March grew by 13 per cent to $187 million, while profit jumped by 82 per cent to $90 million.

• Sun Pharma hits all-time high on Q4 earnings, outlook

  Global brokerage CLSA continues to be positive on Sun Pharma after India's No. 3 drugmaker by sales reported a 23.4 per cent rise in net profit during the fourth-quarter ended March to Rs 1,012 crore.

• Sun Pharma beats Q4 estimates, announces bonus issue

  Sun Pharmaceutical Industries reported a 23.4 per cent rise in quarterly net profit beating market estimates, and India's top drugmaker by market value also announced a bonus share issue.

• Sensex drops 100 points as L&T's Q4 net disappoints Street

  The BSE Sensex slipped sharply in the last hour of trade on Wednesday as engineering and construction major Larsen & Toubro posted below estimates profits for the March quarter. The Sensex came close to breaching the key 20,000 mark amid the broad selloff.

• Sun Pharma boosted by Taro Q4, shares rise

  Taro's gross profit, as a percentage of net sales, rose to 71.6%, compared to 59.6% (YoY).